New study shows CT-measured body fat, not BMI, links obesity to higher lung cancer risk via immune T-cell changes—hinting at prevention through weight loss.
|Videos|January 17, 2019
Evaluating Ruxolitinib With Pegylated Interferon Alfa-2a in Myelofibrosis
Author(s)Jean-Jacques Kiladjian, MD, PhD
Jean-Jacques Kiladjian, MD, PhD, head of clinical investigation at Saint Louis Hospital in Paris, discusses the Ruxopeg trial, a phase I/II trial investigating the combination of ruxolitinib (Jakafi) with pegylated interferon alfa-2a in patients with myeloproliferative neoplasm (MPN)-associated myelofibrosis.
Advertisement
Jean-Jacques Kiladjian, MD, PhD, head of clinical investigation at Saint Louis Hospital in Paris, discusses the Ruxopeg trial, a phase I/II trial investigating the combination of ruxolitinib (Jakafi) with pegylated interferon alfa-2a in patients with myeloproliferative neoplasm (MPN)-associated myelofibrosis (MF).
Advertisement
Related to this article
The IMpactMF trial was discontinued after an independent committee determined imetelstat was unlikely to improve overall survival.
The phase 3 VERIFY trial found that rusfertide improved clinical response, reduced phlebotomy requirements, and eased symptom burden in patients with polycythemia vera receiving standard-of-care therapy.
At Rutgers Cancer Institute, neuro-oncologists met to discuss the latest trends in precision brain cancer care with FET-PET imaging, advanced molecular testing, and same-day multidisciplinary clinics.
Advertisement
Advertisement
Trending on Targeted Onc
1
ESMO 2026: ADCs and New Combinations Advance Lung Cancer Care
2
340B Contract Pharmacy Case Rekindles Scrutiny Over Program Intent
3
Petosemtamab Plus Pembrolizumab Improves OS in PD-L1+ HNSCC
4
ESMO 2026: New Data Advance Prostate, Kidney, and Bladder Cancer Care
5